Xencor (NASDAQ:XNCR) Sets New 1-Year Low – Here’s Why

Xencor, Inc. (NASDAQ:XNCR) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.55 and last traded at $10.81, with a volume of 165586 shares traded. The stock had previously closed at $11.23.

Analysts Set New Price Targets

A number of analysts have commented on XNCR shares. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Performance

The company’s fifty day simple moving average is $15.18 and its two-hundred day simple moving average is $19.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a market capitalization of $682.78 million, a P/E ratio of -3.03 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. As a group, equities analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Institutional Investors Weigh In On Xencor

A number of large investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC lifted its position in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Xencor during the fourth quarter worth about $34,000. GAMMA Investing LLC grew its stake in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV increased its holdings in Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 813 shares during the period. Finally, Quarry LP raised its position in shares of Xencor by 111.4% in the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 2,108 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.